The relative amount of YFP+CD3+ cells in tumor was also significantly decreased in the group that received CCR2+MHC-I−/− HSC + PD-1 (mean YFP+CD3+ cells = 0.597% ± 0.2487, n = 5) relative to the group that received CCR2+HSC + PD-1 (p = < 0.0001). The gene discussed is CCR2; the disease is neoplasm.